PLAGL2 is a zinc finger transcription factor that functions as a DNA-binding transcriptional activator 1. It regulates transcription by RNA polymerase II and exhibits sequence-specific DNA binding activity in the nucleus. Mechanistically, PLAGL2 operates through multiple signaling pathways depending on cellular context. In bladder cancer, PLAGL2 promotes progression by transactivating RACGAP1, which activates RhoA GTPase and disrupts the Hippo pathway, increasing YAP1/TAZ activity 2. In lung cancer, PLAGL2 is transcriptionally activated by E2F1 and promotes cancer stemness 3. PLAGL2 also functions as a transcriptional regulator within a USP10 signaling loop that promotes hepatocellular carcinoma progression via stress-induced epinephrine signaling 4. Clinically, PLAGL2 demonstrates significant disease relevance across multiple cancer types. It is upregulated in rectal, bladder, lung, pancreatic, and hepatocellular carcinomas, correlating with poor prognosis 125. In pancreatic cancer, high PLAGL2 expression promotes epithelial-mesenchymal transition and associates with advanced TNM stage 5. PLAGL2 amplification defines a distinct pediatric CNS embryonal tumor type, with PLAGL2-amplified tumors occurring in infants and toddlers (25% 10-year survival) 6. Conversely, PLAGL2 protects against hyperoxia-induced lung injury in neonatal bronchopulmonary dysplasia by maintaining HIF-1α/VEGF signaling 7. PLAGL2 emerges as a potential prognostic biomarker and therapeutic target across malignancies.